ClearPoint Neuro (CLPT) vs Neuropace (NPCE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Neuropace (NPCE) has outperformed ClearPoint Neuro (CLPT) over the past year, losing 44.6% versus a loss of 50.0%. Over five years, NPCE leads with a -32.8% price change compared with -50.0% for CLPT. Neuropace is the larger company by market cap ($273.9 million vs $221.5 million), about 1.2 times the size.
Neuropace converts more of its revenue into profit, with a net margin of -21.5% versus -69.1%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CLPT | NPCE |
|---|---|---|
| Share price | $6.91 | $7.95 |
| Market cap | $221.49M | $273.89M |
| 1-day change | -5.47% | -2.33% |
| YTD return | -49.49% | -48.51% |
| 1-year return | -50.00% | -44.60% |
| 5-year return | -50.04% | -32.80% |
| EPS (TTM) | $-1.21 | $-0.56 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $36.97M | $99.99M |
| Revenue growth (YoY) | +17.78% | +25.13% |
| Net income (latest FY) | $-25.54M | $-21.46M |
| Gross margin | 61.38% | 77.23% |
| Operating margin | -65.36% | -16.34% |
| Net margin | -69.08% | -21.47% |
| 52-week high | $19.63 | $19.60 |
| 52-week low | $6.85 | $5.46 |
| Distance from 52-week high | -64.80% | -59.44% |
| Analyst consensus | none | buy |
| Avg. price target upside | +211.14% | +53.71% |
| Average volume | 701.64K | 270.76K |
| Shares outstanding | 32.05M | 34.45M |
| Employees | 172 | 216 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Neuropace is more profitable, keeping -21.5 cents of every revenue dollar as net income versus -69.1 cents for ClearPoint Neuro.
- Neuropace grew revenue faster in its latest fiscal year (+25.13% vs +17.78%).
About ClearPoint Neuro
CLPT stock →ClearPoint Neuro, Inc., a commercial-stage medical device company, focuses on the development and commercialization of platforms for performing minimally invasive surgical procedures in the brain in the United States. The company offers ClearPoint systems, such as ClearPoint hardware, which includes head fixation frame, computer workstation, and in-room monitor; and ClearPoint disposables, which consist of SmartFrame trajectory device, a hand controller and related accessories, and its SmartFlow Neuro cannula.
Health Care · Medical/Dental Instruments · 172 employees
About Neuropace
NPCE stock →NeuroPace, Inc. operates as a medical device company in the United States.
Health Care · Medical/Dental Instruments · 216 employees
CLPT vs NPCE FAQ
Which is bigger, ClearPoint Neuro or Neuropace?
Neuropace (NPCE) is larger, with a market capitalization of $273.89M compared with $221.49M for ClearPoint Neuro (CLPT).
Which stock has performed better over the past year, CLPT or NPCE?
NPCE returned -44.60% over the past 12 months, compared with -50.00% for CLPT (price return, excluding dividends). Past performance does not predict future results.
Are ClearPoint Neuro and Neuropace in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.